DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Seribantumab is an investigational drug.
There have been 7 clinical trials for Seribantumab. The most recent clinical trial was a Phase 1 trial, which was initiated on March 21st 2021.
The most common disease conditions in clinical trials are Breast Neoplasms, Endometrial Neoplasms, and Triple Negative Breast Neoplasms. The leading clinical trial sponsors are Merrimack Pharmaceuticals, Sanofi, and Ottawa Hospital Research Institute.
There are three US patents protecting this investigational drug and eleven international patents.
Recent Clinical Trials for Seribantumab
|Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab||Ottawa Hospital Research Institute||Phase 2|
|A Phase 2 Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Cancer||Elevation Oncology||Phase 2|
|Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer||Merrimack Pharmaceuticals||Phase 2|
Top disease conditions for Seribantumab
Top clinical trial sponsors for Seribantumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Seribantumab||⤷ Try it Free||Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors||Merrimack Pharmaceuticals, Inc. (Cambridge, MA)||⤷ Try it Free|
|Seribantumab||⤷ Try it Free||Salt of EGFR inhibitor, crystalline form and uses thereof||SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)||⤷ Try it Free|
|Seribantumab||⤷ Try it Free||Binding-triggered transcriptional switches and methods of use thereof||The Regents of the University of California (Oakland, CA)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Seribantumab||Australia||AU2016343517||2035-10-19||⤷ Try it Free|
|Seribantumab||Canada||CA3001655||2035-10-19||⤷ Try it Free|
|Seribantumab||China||CN106588943||2035-10-19||⤷ Try it Free|
|Seribantumab||European Patent Office||EP3365344||2035-10-19||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|